Top 5 Overbought Healthcare Stocks

Published:

Healthcare has been one of the best performing sectors over the past three years. Out of the 1,907 listed North American ETFs, the ProShares Ultra Nasdaq Biotechnology (NASDAQ: BIB) and the Direxion Daily Healthcare Bull 3X Shares (NYSE: CURE) are the best performing ones, returning 420% and 412%, respectively. However, we are starting to notice a pullback in certain stocks such as Novadaq Technologies Inc. (TSX: NDQ) and HMS Holdings Corp. (NASDAQ: HMSY), which have dropped 23% and 53%, respectively. The stocks on our list today may see similar declines during the next year.

Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) – $77.77

Pharmaceuticals

Eagle Pharmaceuticals, Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company focused on developing and commercializing injectable products. It develops products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially injectable products. Its two most advanced product candidates are EP-3101 (bendamustine RTD), an intravenous version of the chemotherapeutic agent that is marketed by Teva under the brand name Treanda, and Ryanodex (dantrolene for MH), and an intravenous version of an approved treatment for malignant hyperthermia.

  • Market Cap: $1,597,244,964
  • Revenues (LTM): $63,211,736
  • YTD Price Change: 4.02
  • Average Daily Volume (30 days): 101,861

>> Read More: Dividend Killers? 5 Companies That Could Offend

Exelixis Inc. (NASDAQ: EXEL) – $5.56

Biotechnology & Medical Research

Exelixis Inc. is a biopharmaceutical company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States.

  • Market Cap: $1,651,224,907
  • Revenues (LTM): $37,478,543
  • YTD Price Change: 2.86
  • Average Daily Volume (30 days): 1,424,873

Heron Therapeutics Inc. (NASDAQ: HRTX) – $37.68

Biotechnology & Medical Research

Heron Therapeutics, Inc. is a biotechnology company that uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. The Company’s product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV).

  • Market Cap: $1,705,607,069
  • Revenues (LTM): $0
  • YTD Price Change: 2.61
  • Average Daily Volume (30 days): 272,506

>> Read More: Junior Gold Miner Shines on Operational Results

Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) – $19.62

Pharmaceuticals

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder), and ADHD.

  • Market Cap: $1,254,762,437
  • Revenues (LTM): $174,023,144
  • YTD Price Change: 1.37
  • Average Daily Volume (30 days): 263,658

Nobilis Health Corp. (TSX: NHC) – $6.63

Healthcare Facilities & Services

Nobilis Health Corp., formerly Northstar Healthcare Inc., is a Canada-based company that partners with physicians in the development and management of ambulatory surgical centers (ASCs). The Company indirectly acquire and/or manage ambulatory surgery centers (ASCs) and healthcare facilities in the United States.

  • Market Cap: $451,459,942
  • Revenues (LTM): $173,382,852
  • YTD Price Change: 0.94
  • Average Daily Volume (30 days): 432,362

Related articles

Recent articles